BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemiaCharles Herbaux, Matthew S. Davids, Mary C. Collins et al.|Blood|2021Cited by 37
THE COMBINATION OF VENETOCLAX AND IBRUTINIB IS EFFECTIVE IN RELAPSED/REFRACTORY T‐PROLYMPHOCYTIC LEUKEMIA AND INFLUENCES BCL‐2‐FAMILY MEMBER DEPENDENCIESChristoph Kornauth, Philipp B. Staber, Charles Herbaux et al.|Hematological Oncology|2019Cited by 10
Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemiaChristoph Kornauth, Philipp B. Staber|Haematologica|2021Cited by 9